Imatinib Mesylate
Mostrando 13-24 de 35 artigos, teses e dissertações.
-
13. Comment on: determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to monitor treatment compliance
Rev. Bras. Hematol. Hemoter.. Publicado em: 2013
-
14. In vitro inhibitory effects of imatinib mesylate on stromal cells and hematopoietic progenitors from bone marrow
Imatinib mesylate (IM) is used to treat chronic myeloid leukemia (CML) because it selectively inhibits tyrosine kinase, which is a hallmark of CML oncogenesis. Recent studies have shown that IM inhibits the growth of several non-malignant hematopoietic and fibroblast cells from bone marrow (BM). The aim of the present study was to evaluate the effects of IM
Braz J Med Biol Res. Publicado em: 25/09/2012
-
15. Avaliação da associação dos polimorfismos C1236T, C3435T e G2677T/A no gene ABCB1 a marcadores de resposta ao mesilato de imatinibe em pacientes com leucemia mieloide crônica / Evaluation of the association of C1236T, C3435T and G2677T/A polymorphisms on ABCB1 gene to response markers to imatinib mesylate in patients with chronic myeloid leukemia
A leucemia mieloide crônica (LMC) é uma expansão clonal da célula progenitora hematopoiética, traduzindo-se por hiperplasia mielóide, leucocitose, neutrofilia, basofilia e esplenomegalia. O cromossomo Filadélfia é característico da doença, sendo produto da translocação t(9;22) (q34;q11), resultando na fusão dos genes ABL e BCR. Esta fusão gera
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 01/02/2011
-
16. Assessment of fibrosis and vascularization of bone marrow stroma of chronic myeloid Leukemia patients treated with imatinib mesylate and their relationship with the cytogenetic response
A Leucemia Mielóide Crônica (LMC) é uma doença mieloproliferativa caracterizada pela presença do cromossomo Filadélfia (translocação entre os cromossomos 9 e 22), que resulta na formação da proteína híbrida BCR-ABL. Atualmente o tratamento de pacientes com LMC é realizado com mesilato de imatinibe (MI), o qual promove a eliminação das células
Brazilian Journal of Pharmaceutical Sciences. Publicado em: 2011-06
-
17. Importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance
Imatinib mesylate was the first BCR-ABL-target agent approved for the treatment of chronic myeloid leukemia. Although most patients respond well to imatinib therapy, the literature shows that one third develops resistance or intolerance. The timing of second-line treatment after failure of initial treatment may have a significant impact on long-term outcome.
Revista Brasileira de Hematologia e Hemoterapia. Publicado em: 2011-02
-
18. Tumor do estroma gastrintestinal (GIST): relato de caso
The authors report a case of a male patient in his forties with progressive abdominal pain associated with weight loss, dyspnea, and edema of the inferior limbs, culminating in a surgical acute abdomen. A segmental enterectomy containing a lesion of about 10cm in diameter was performed. It was later confirmed, by means of immuno-hystochemistry, as being a Ga
Revista do Colégio Brasileiro de Cirurgiões. Publicado em: 2011-02
-
19. Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia
Chronic myeloid leukemia (CML) is rare in the pediatric population, accounting for 2-3% of childhood leukemia cases, with an annual incidence of one case per million children. The low toxicity profile of imatinib mesylate has led to its approval as a front-line therapy in children for whom interferon treatment has failed or who have relapsed after allogeneic
Brazilian Journal of Medical and Biological Research. Publicado em: 2010-06
-
20. CONCEPÇÕES SOBRE O CÂNCER E O SEU TRATAMENTO NO CONTEXTO HOSPITALAR E ESCOLAR / THE CONCEPTIONS ABOUT CANCER AND ITS TREATMENT IN THE HOSPITAL AND ACADEMICAL CONTEXT
In this study was analysed the conceptions about cancer and its treatment on the educational context under two aspects: in the hospital and at school, though active intervention of the pharmaceutical professional. In the hospital ambient was elected the pharmacy service of Santa Maria university hospital, in the chemotherapy department. The patients who were
Publicado em: 2010
-
21. Immunohistochemical Expression of |C-kit (CD 117) protein in Retinoblastoma. / Expressão imuno-histoquímica da proteína C-kit no Retinoblastoma.
Purpose: C-kit is a transmembrane tyrosine kinase protein thought to play an important role in tumorigenesis. With the development of the compound Imatinib Mesylate which specifically inhibits tyrosine kinase receptors, C-kit has emerged as a potential therapeutic target. This study aims to determine the immunoexpression of C-kit in retinoblastoma and correl
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 30/09/2009
-
22. Molecular monitoring of patients with chronic myeloid leukemia treated with imatinib mesylate and evaluation of treatment resistance mechanisms: mutation of BCR-ABL and expression of MDR1 and BCRP genes / Acompanhamento molecular de pacientes com leucemia mielóide crônica tratados com mesilato de imatinibe e avaliação dos mecanismos de resistência ao tratamento: mutação do gene BCR-ABL e expressão dos genes MDR1 e BCRP
Chronic myeloid leukemia is characterized by t(9;22) translocation. The chimeric gene BCR-ABL encodes a p210BCRABL protein with constitutive tyrosine kinase activity which is directly related to CML pathogenesis. The imatinib mesylate, a tyrosine kinase inhibitor, is the first-choice treatment for patients in chronic phase but some patients show primary resi
Publicado em: 2009
-
23. Avaliação dos efeitos cardiovasculares do imatinibe em pacientes com leucemia mielóide crônica.
Background: Imatinib mesylate (IM), a tyrosine kinase inhibitor that targets BCR-ABL, PDGFRA and c-kit, has become the first line of therapy for patients with chronic myeloid leukemia (CML) and advanced gastrointestinal stromal tumors (GIST). A recent publication suggests that IM might have myocardial toxicity. It reported ten individuals who developed sever
Publicado em: 2008
-
24. The effect of tyrosine-kinase inhibitors on the apoptosis machinery in chronic myeloid leukemia / Efeitos dos inibidores de tirosina-quinase sobre a maquinaria apoptótica na leucemia mielóide crônica
Chronic myeloid leukemia (CML) is a myeloproliferative disease resultant of a clonal expansion of pluripotent hematopoietic stem cells. The CML physiopathology is associated with a translocation between chromosomes 9 and 22 long arms, promoting the formation of a bcr-abl neogene, which codifies the Bcr-Abl protein. The Bcr-Abl oncoprotein presents tyrosine-k
Publicado em: 2007